Spots Global Cancer Trial Database for Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
Official Title: Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
Study ID: NCT03433534
Interventions
Study Description
Brief Summary: To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration. Collection of standard data prospectively.
Detailed Description: Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in terms of efficacy and side effects. Like others monoclonal antibodies, a relation between concentration and effects of nivolumab may exist. The aim of this study is to assess the relationship between blood concentration of nivolumab and progression free survival, overall survival and side effects on the one hand, and on the other to describe pharmacokinetic of nivolumab
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medical oncology department, University Hospital, Tours, Tours, , France
Pneumology department, University Hospital, Tours, Tours, , France
Contact Details
Name: Claude Linassier
Affiliation: University Hospital, Tours
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
